Advertisement

A 2019 reproductive update from the Midwest Reproductive Symposium International

  • Jessica R. ZoltonEmail author
  • Gretchen G. Collins
  • Eleni A. Greenwood
  • Elie Hobeika
  • Roohi Jeelani
  • Angeline Beltsos
  • William G. Kearns
Commentary
  • 28 Downloads

Abstract

“Mystery, Medicine, and the Magnificent Mile,” the theme for the annual Midwest Reproductive Symposium International (MRSi) in Chicago, IL, captured the attention of reproductive professionals all over the world. Each year, the conference agenda encompasses emerging technologies in assisted reproduction, updates in the management of reproductive diseases, and common challenges encountered in clinical practice. The structure of the meeting, offering a mixture of lectures, panel discussions, and interactive workshops, creates a collaborative environment for physicians, geneticists, embryologists, nurses, mental health professionals, basic scientists, business administrative professionals, reproductive endocrinology and infertility fellows, and obstetrics and gynecology residents. The goal of the MRSi meeting is to provide all reproductive professionals the opportunity to exchange ideas, foster relationships, and deliver quality patient care. As the field continues to evolve, MRSi provides an exciting venue to uncover the mysteries of reproductive medicine with enthusiasm and collaboration.

Keywords

infertility genetics reproductive endocrinology continuing medical education medical conference 

Notes

Compliance with ethical standards

Disclaimer

The views expressed in this manuscript are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the US Government.

References

  1. 1.
    Calafat AM, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 2008;116(1):39–44.CrossRefGoogle Scholar
  2. 2.
    Berman T, et al. Phthalate exposure among pregnant women in Jerusalem, Israel: results of a pilot study. Environ Int. 2009;35(2):353–7.CrossRefGoogle Scholar
  3. 3.
    Ehrlich S, et al. Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod. 2012;27(12):3583–92.CrossRefGoogle Scholar
  4. 4.
    Hauser R, et al. Urinary phthalate metabolite concentrations and reproductive outcomes among women undergoing in vitro fertilization: results from the EARTH Study. Environ Health Perspect. 2016;124(6):831–9.CrossRefGoogle Scholar
  5. 5.
    Kawamura K, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013;110(43):17474–9.CrossRefGoogle Scholar
  6. 6.
    Youssef MA, et al. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Hum Reprod. 2017;32(1):112–8.PubMedGoogle Scholar
  7. 7.
    Bassiouny YA, et al. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105(3):697–702.CrossRefGoogle Scholar
  8. 8.
    Li XL, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(12):e6443.CrossRefGoogle Scholar
  9. 9.
    Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–79.CrossRefGoogle Scholar
  10. 10.
    Mejia RB, et al. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571–578.e1.CrossRefGoogle Scholar
  11. 11.
    Marci R, et al. Presence of HHV-6A in endometrial epithelial cells from women with primary unexplained infertility. PLoS One. 2016;11(7):e0158304.CrossRefGoogle Scholar
  12. 12.
    Devine K, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109(2):266–75.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesdaUSA
  2. 2.Wisconsin Fertility InstituteMiddletonUSA
  3. 3.Department of Obstetrics, Gynecology and Reproductive SciencesUniversity of CaliforniaSan FranciscoUSA
  4. 4.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyUniversity of Illinois College of MedicineChicagoUSA
  5. 5.Vios Fertility InstituteChicagoUSA
  6. 6.Advagenix, Rockville, MD, Department of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations